NCT04925544View on ClinicalTrials.gov

Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

January 25, 2022

Primary Completion Date

June 17, 2026

Study Completion Date

June 17, 2027

Conditions
Nasopharyngeal CancerEpstein-Barr Virus Related Carcinoma
Interventions
DRUG

VK-2019

VK-2019 binds to EBNA1 and inhibits EBNA1 DNA binding activity. VK-2019 API is synthesized by Anthem BioSciences Pvt. Ltd and formulated into capsules by Emerson Resources Inc,

Trial Locations (1)

94305

Stanford University, Stanford

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Cancer Institute (NCI)

NIH

lead

Stanford University

OTHER